European summit - GSK: De Wever believes the pharmaceutical sector must be protected from the US and China

Le SoirIndependentProgressive9 hr. ago

The pharmaceutical company GlaxoSmithKline (GSK) plans to cut over 1,200 jobs as part of a restructuring effort, which has drawn criticism from Solidaris and Setca, two Belgian organizations representing healthcare and workers' interests. They argue that this decision reflects a broader trend in the pharmaceutical industry where companies prioritize highly profitable treatments, particularly in oncology, at the expense of other areas of their operations. The groups criticize GSK’s decision despite the company’s significant profits, including €2.4 billion in net income from its vaccines division in 2025, along with substantial public funding and reimbursements from the national health system. Solidaris and Setca claim that the high prices of cancer treatments give pharmaceutical firms excessive power in price negotiations, forcing governments to comply with costly reimbursement demands. They call for stronger regulation to ensure fair pricing and prevent job losses in the healthcare sector.

Bias read (Progressive): The article frames the restructuring at GSK as a consequence of 'a race for excessive profits,' emphasizing the negative impact on employment and public healthcare. It criticizes the pharmaceutical industry for prioritizing profit over public interest and calls for government intervention to set 'fa

Le SoirIndependentCenter17 hr. ago

The Belgian Prime Minister, Bart De Wever, commented during the European summit in Brussels on the challenges faced by the British pharmaceutical giant GSK due to pressures from the United States and China. He noted that U.S. policies require GSK to invest heavily in America while restricting vaccine imports, putting pressure on companies like GSK. Additionally, he criticized China’s approach to clinical trials as unfair competition supported by massive subsidies. De Wever emphasized the need to integrate and protect the European market to remain competitive, warning against adopting protectionist measures that could harm the sector. He highlighted that Belgium’s pharmaceutical industry requires protection not due to competitiveness issues but because of external pressures from both the U.S. and China. The discussion comes amid growing European unity on addressing trade practices with China.

Bias read (Center): The article presents the views of the Belgian Prime Minister regarding international trade pressures on the pharmaceutical sector. It includes direct quotes from De Wever expressing concerns over U.S. and Chinese policies affecting GSK. However, the article does not exhibit overtly biased language,

RTBF InfoState / PublicCenteryesterday

The article discusses how Belgium, historically a central hub for GlaxoSmithKline (GSK)'s vaccine production, is bearing the consequences of the pharmaceutical giant's strategic shift. This shift has likely involved moving manufacturing operations or research focus away from Belgium, impacting local jobs and economic stability. The article explores the reasons behind GSK's decision and the effects on Belgium's role in global vaccine production.

Bias read (Center): The article appears to present a balanced view of the situation, discussing both GSK's strategic decisions and their impact on Belgium without overtly favoring either side. It does not exhibit strong ideological language or one-sided sourcing.